Navigation Links
Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia

ho do not meet the DSM-IV criteria, and experience considerable daytime impairment and symptom frequency. Study Estimates Insomnia Costs at $13.5 Billion Annually in the U.S. Labor Force -- The objective of this study was to estimate the annual indirect costs in the U.S. Labor Force of DSM-IV diagnosed chronic primary insomnia. -- Results showed that the annual indirect cost of chronic primary insomnia in the U.S. labor force, as diagnosed by the DSM-IV, is estimated to be $13.5 billion which reflects absenteeism from work directly attributable to an insomnia diagnosis, and productivity losses attributable to the insomnia-related incidence of accidents and chronic illnesses (depression, alcohol and/or substance abuse/dependence) -- The authors concluded that a DSM-IV diagnosis of insomnia leads to considerable productivity losses in the U.S. labor force. Interventions to reduce the severity of chronic primary insomnia among U.S. workers could substantially reduce its indirect cost burden.

Pharmaceutical Treatment of Insomnia Reduces Overall Economic Costs of Insomnia

    --  The objective of this study was to estimate the direct and indirect

        costs of treated and untreated insomnia in an employed population.

    --  Results showed that insomnia patients who were initially treated with

        a non-benzodiazepine hypnotic within two weeks of diagnosis had a much

        lower cost burden that those who were not treated for their insomnia.

        Demonstrating that treating insomnia was cost-effective relative to

        non-treatment, or delayed treatment.


Study Shows that Existing Next Day Impairment Measures May Not Capture True Impact of Insomnia

    --  The goal of this study was to evaluate the commonly used tests of

        "n
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
3. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:6/30/2015)... – Small Cap IR issues report. Recently, Arrayit Corporation ... blood card technology to Vivos, Global Genome Vault, the ... an impervious, impenetrable and permanent DNA storage vault, able ... Earth, a safe and secure nuclear blast-proof, underground shelter ... rapid collection, separation, drying and storage of human genomic ...
(Date:6/30/2015)... N.C. , June 30, 2015  Marken, the ... to the life sciences industry, has been granted permission ... patient shipment of clinical drug product in Korea.  This ... South Korea to continue receiving their clinical ... System (MERS). The emergency was caused by ...
(Date:6/30/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... of StockholdersWhen:Tuesday, June 30 at 5:10 p.m. ET / ... log onto our website listed above.   ... event, a replay of the webcast will be available ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 2Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 3
... Feb. 23 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical trial of Unit Dose Budesonide (UDB) ... The Company announced that the clinical,trial did not ... by,changes from baseline in nighttime and daytime composite ...
... BCRX ) today announced that the full ... peramivir in patients hospitalized for influenza was presented by ... Professor, Divisions of Infectious Diseases and Organ Transplantation at ... the XI International Symposium on Respiratory Viral Infections taking ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 2Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 4Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 5
(Date:6/30/2015)... ... 30, 2015 , ... University Post-Acute Rehab recently released a ... rehab center’s patients and their experiences at the facility. Medicare granted University Post-Acute ... Each patient attests to the high rating, which is predominantly based on cleanliness, ...
(Date:6/30/2015)... ... 2015 , ... According to a June 15th report from USC ... sensory stimuli can be used to “decrease children’s anxiety and negative responses during oral ... will compare patient experience in a “typical dental environment” with one that provides “visual, ...
(Date:6/30/2015)... ... 30, 2015 , ... Broadway by the Sea posted its newest YouTube video ... testimonials. Medicare rated the care center as a five-star location based on a comprehensive ... future patients a firsthand look at the facility’s satisfied residents. , “In this ...
(Date:6/30/2015)... ... June 30, 2015 , ... After many requests from ... its here, http://www.express-glasses.com is proud to announce its collaboration with DHL ... shipping with DHL Express when calling or visiting the express glasses website. express ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... a federal multidistrict litigation now underway in the U.S. District Court, Eastern District ... Conference. According to the Court’s calendar, that conference has now been scheduled for ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3
... November 2, 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 28 The goal of ... Paul Angulo, was to determine the,effects of fatty liver disease ... is especially important as nonalcoholic fatty liver disease,(NAFLD) is the ...
... 28 CoLucid Pharmaceuticals, Inc., an,innovative biotechnology ... disorders, announced today that it has appointed ... In this position, Hogan will apply more,than ... and biopharmaceutical,industries to drive CoLucid,s business development ...
... WOBURN, Mass., Oct. 28 Galenea Corp.,today announced ... and its,academic collaborators that gives Galenea a license ... other related disorders. The license grants,Galenea the exclusive ... indole-based agonists., The licensed compounds have demonstrated ...
... Brain Injury Association (CALBIA), a non-profit membership ... those affected by brain injury, together with the ... representing individuals sustaining traumatic brain injury , ... nation’s most important professional medical/legal conferences dealing with ...
... hemoglobin A1c monitoring market is forecast to surpass $272 million by ... population. Other growth drivers include greater glucose control and product innovations ... ... Jose, CA (PRWEB) October 28, 2008 -- World Health Organization forecasts ...
... you,re an individual watching the stock market crash or ... in the journal Psychological Science, examines how ... their behavior more than young adults when under stress ... looked at how stress affects decision making, even though ...
Cached Medicine News:Health News:Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 2Health News:CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development 2Health News:CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development 3Health News:Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity 2Health News:Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity 3Health News:California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008 2Health News:California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008 3Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:Stress affects older adults more than young adults 2
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
This revolutionary system combines the CSZ Head Wrap and Patient Vest for a non-invasive whole body hypothermia system. This method of cooling the patient allows for early treatment that is fast, cos...
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Medicine Products: